Resumes
Resumes
June Zou Phones & Addresses
-
Richmond, CA
-
Elk Grove, CA
-
6531 Park Riviera Way, Sacramento, CA 95831
-
San Diego, CA
-
Davis, CA
Publications
Us Patents
Ancca As A Diagnostic Biomarker And Therapeutic Target For Breast Cancers
View pageUS Patent:
20130261167, Oct 3, 2013
Filed:
Sep 23, 2011
Appl. No.:
13/825309
Inventors:
Hong-Wu Chen - Sacramento CA, US
June X. Zou - Sacramento CA, US
June X. Zou - Sacramento CA, US
Assignee:
The Regents Of The University Of California - Oakland CA
International Classification:
G01N 33/68
C12N 15/113
C12Q 1/68
C12N 15/113
C12Q 1/68
US Classification:
514 44 A, 435 74, 435 612, 435375
Abstract:
The present invention provides methods of diagnosing breast cancer, confirming a diagnosis of breast cancer, predicting the survival of a breast cancer patient, and providing a therapeutic target of treatment in a breast cancer patient by measuring relatively increased expression levels of ANCCA. Expression levels of ANCCA can be measured be determining the levels mRNA or protein. The expression levels can be compared to a predetermined threshold level or to a control, e.g., a positive or negative control.
Methods For Treating Cancer With Rorgamma Inhibitors
View pageUS Patent:
20210161837, Jun 3, 2021
Filed:
Jun 30, 2020
Appl. No.:
16/917818
Inventors:
- Oakland CA, US
June X. Zou - Davis CA, US
Junjian Wang - Davis CA, US
Demin Cai - Davis CA, US
Yong Xu - Guangzhou, CN
Xiaoqian Xue - Guangzhou, CN
Yan Zhang - Guangzhou, CN
June X. Zou - Davis CA, US
Junjian Wang - Davis CA, US
Demin Cai - Davis CA, US
Yong Xu - Guangzhou, CN
Xiaoqian Xue - Guangzhou, CN
Yan Zhang - Guangzhou, CN
Assignee:
The Regents of the University of California - Oakland CA
Guangzhou Institutes of Biomedicine and Health - Guangzhou
U.S. Government represented by the Department of Veterans Affairs - Washington DC
Guangzhou Institutes of Biomedicine and Health - Guangzhou
U.S. Government represented by the Department of Veterans Affairs - Washington DC
International Classification:
A61K 31/167
C07C 205/11
A61K 31/58
A61K 31/277
A61K 31/4166
A61K 45/06
A61P 35/00
A61K 31/138
A61K 31/222
A61K 31/337
C07C 205/11
A61K 31/58
A61K 31/277
A61K 31/4166
A61K 45/06
A61P 35/00
A61K 31/138
A61K 31/222
A61K 31/337
Abstract:
The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
Methods For Treating Cancer With Rorgamma Inhibitors
View pageUS Patent:
20190192454, Jun 27, 2019
Filed:
Jul 17, 2018
Appl. No.:
16/038069
Inventors:
- Oakland CA, US
June X. Zou - Davis CA, US
Junjian Wang - Davis CA, US
Demin Cai - Davis CA, US
Yong Xu - Guangzhou, CN
Xiaoqian Xue - Guangzhou, CN
Yan Zhang - Guangzhou, CN
June X. Zou - Davis CA, US
Junjian Wang - Davis CA, US
Demin Cai - Davis CA, US
Yong Xu - Guangzhou, CN
Xiaoqian Xue - Guangzhou, CN
Yan Zhang - Guangzhou, CN
Assignee:
The Regents of the University of California - Oakland CA
Guangzhou Institutes of Biomedicine and Health - Guangzhou
U.S. Government represented by the Department of V eterans Affairs - Washington DC
Guangzhou Institutes of Biomedicine and Health - Guangzhou
U.S. Government represented by the Department of V eterans Affairs - Washington DC
International Classification:
A61K 31/167
A61P 35/00
A61K 31/138
A61K 31/337
A61K 31/222
A61P 35/00
A61K 31/138
A61K 31/337
A61K 31/222
Abstract:
The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
Methods For Treating Cancer With Rorgamma Inhibitors
View pageUS Patent:
20180085348, Mar 29, 2018
Filed:
Sep 11, 2017
Appl. No.:
15/701122
Inventors:
- Oakland CA, US
June X. Zou - Davis CA, US
Junjian Wang - Davis CA, US
June X. Zou - Davis CA, US
Junjian Wang - Davis CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 31/403
A61K 31/655
A61K 31/4725
A61K 31/496
A61K 31/4166
A61K 31/713
C12N 15/113
A61K 31/185
A61K 31/18
A61K 31/655
A61K 31/4725
A61K 31/496
A61K 31/4166
A61K 31/713
C12N 15/113
A61K 31/185
A61K 31/18
Abstract:
The present invention provides compositions, methods, and kits comprising one or more RORĪ³ inhibitors, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma, and glioma.